Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.

Abstract

Natural polymers have gained significant attention as materials for the development of biocompatible nanomedicines, offering promising potential for the targeted treatment of colon cancer. These biopolymers are derived out of renewable resources and possess many beneficial characteristics such as biodegradability, low immunogenicity and easy functionalisation to allow precise targeting, making them highly applicable to nanomedicine applications. They can be used to prepare nanoparticles that can effectively deliver therapeutic agents to tumor sites, improving therapeutic effects and reducing systemic toxicity. In addition, the versatile chemical structures of natural polymers allow conjugation with targeting ligands, which allows increased specificity in colon cancer therapy. However, despite these benefits, there are still a number of challenges in the development and clinical translation of natural polymer-based nanomedicines. The complexity of nanoparticles design, including careful control of particle size, physicochemical properties of the surface, and drug-loading capacity, makes the synthesis process and scale-up difficult. Moreover, the realization of consistent and reproducible production at an industrial level is a significant obstacle. Also, although the phenomenon of enhanced permeability and retention (EPR) increases passive tumour targeting, its heterogeneity in colorectal cancer patients compromises predictability of therapeutic responses, which necessitates individualised treatment plans. The possible cytotoxicity of nanoparticles, especially those with complex structures, highlights the need to have more realistic preclinical models to carefully test safety and therapeutic efficacy. The review provides an in-depth evaluation of the present situation of natural polymer-based nanomedicines in the treatment of colon cancer, their unique properties, therapeutic potential, and the challenges that need to be overcome to achieve clinical success. Novel technologies, including microfluidic systems and individualised treatment plans, are given particular focus as they are likely to reduce these challenges and open the path to safer, more effective, and scalable nanomedicine solutions to colon cancer.